Search Result

Isoforms Recommended:	CDK6

Results for "

cdk6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (134) AAK1 (2) Akt (1) AMPK (3) Androgen Receptor (1) Apoptosis (38) ASK1 (1) Aurora Kinase (1) Autophagy (1) Bcl-2 Family (2) c-Myc (1) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (6) CXCR (3) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (3) Drug Derivative (1) Drug Metabolite (3) E3 Ligase Ligand-Linker Conjugates (2) Ephrin Receptor (1) Epigenetic Reader Domain (6) ERK (2) Estrogen Receptor/ERR (1) FGFR (1) FLT3 (1) Glutathione Peroxidase (1) GSK-3 (1) HDAC (1) HSP (1) Insulin Receptor (1) Interleukin Related (1) IRAK (1) Isotope-Labeled Compounds (5) Itk (1) JNK (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (3) LIM Kinase (LIMK) (1) MAP4K (1) MELK (1) Mitochondrial Metabolism (2) mTOR (1) NF-κB (3) p38 MAPK (1) PARP (4) PDGFR (1) PI3K (2) Pim (2) PKC (3) PROTACs (19) Protease Activated Receptor (PAR) (1) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (12) Salt-inducible Kinase (SIK) (1) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Smo (1) SnRK (1) SOD (1) STAT (1) Target Protein Ligand-Linker Conjugates (1) Telomerase (1) ULK (1) VEGFR (2) Wee1 (3) Wnt (5) β-catenin (3)
By Research Areas:	Cancer (139) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (12)
Click Chemistry:	PROTAC Synthesis (1) Azide (1) Alkynes (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

150

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16297A

Abemaciclib 115+ Cited Publications LY2835219	CDK	Neurological Disease Cancer
Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-16297

Abemaciclib methanesulfonate 115+ Cited Publications LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-50767C

Palbociclib hydrochloride 215+ Cited Publications PD-0332991 hydrochloride	CDK	Cancer
Palbociclib (PD 0332991) hydrochloride is an orally active selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-N0636

Eriocitrin 5 Publications Verification Eriodictyol 7-rutinoside; Eriodictyol 7-O-rutinoside	Apoptosis	Cancer
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-114177

Ebvaciclib 4 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK), with K_i* values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-101467

Trilaciclib 1 Publications Verification G1T28	CDK	Cancer
Trilaciclib (G1T28) is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-50940

AT7519 10+ Cited Publications AT7519M	CDK Apoptosis	Cancer
AT7519 (AT7519M) as a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6* dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-111556

BSJ-03-123 5 Publications Verification	PROTACs CDK	Cancer
BSJ-03-123 is a PROTAC connected by ligands for Cereblon and *CDK* as a potent and novel *CDK6*-selective small-molecule degrader.

HY-112272

Lerociclib 2 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-12624

Narazaciclib 2 Publications Verification ON123300	CDK AMPK PDGFR	Cancer
Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits *CDK4* (IC₅₀=3.9 nM), Ark5 (IC₅₀=5 nM), PDGFRβ (IC₅₀=26 nM), FGFR1 (IC₅₀=26 nM), RET (IC₅₀=9.2 nM), and FYN (IC₅₀=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors . Narazaciclib inhibits *CDK6* with an IC₅₀ of 9.82 nM .

HY-116035

Nimbolide 2 Publications Verification	Wnt NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-148530

YX-2-107	PROTACs CDK	Cancer
YX-2-107 is a PROTAC (IC₅₀= 4.4 nM) that selectively degrades *CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1* expression in vitro and inhibits the development of Ph ⁺ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph ⁺) acute lymphoblastic leukemia (ALL) .

HY-16297AR

Abemaciclib (Standard) LY2835219 (Standard)	Reference Standards CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-111361

FN-1501 2 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and *CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin* D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-130296

Palbociclib-propargyl PROTAC cdk6 ligand 1	Ligands for Target Protein for PROTAC	Cancer
Palbociclib-propargyl is a ligand for target protein *CDK6* for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC₅₀ of 2.1 nM for CDK6 . Palbociclib-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-45661

Inixaciclib NUV-422	CDK	Neurological Disease Cancer
Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of *CDK2, CDK4* and *CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6* inhibitor-resistant HR ⁺ HER2 ^- metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .

HY-136252

BSJ-04-132	PROTACs CDK	Cancer
BSJ-04-132 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4* degrader (PROTAC), with IC₅₀s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity .

HY-163786

*PROTAC CDK4/6 degrader 1*	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 is a CDK4/CDK6 PROTAC degrader, with DC₅₀ values of 10.5 nM and 2.5 nM, respectively. PROTAC CDK4/6 degrader 1 inhibits the proliferation of Jurkat cells (IC₅₀ = 0.18 μM), arrests the cell cycle at the G1 phase, and induces apoptosis. PROTAC CDK4/6 degrader 1 can be used for cancer research.

HY-50943

AT7519 Hydrochloride 10+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-128669

Abemaciclib metabolite M2 2 Publications Verification LSN2839567	CDK Drug Metabolite	Cancer
Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent *CDK4* and *CDK6* inhibitor, with IC₅₀s of 1.2 and 1.3 nM, respectively. Anti-cancer activity .

HY-101467A

Trilaciclib hydrochloride 1 Publications Verification G1T28 hydrochloride	CDK	Cancer
Trilaciclib (G1T28) hydrochloride is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-50767S

Palbociclib-d8 PD 0332991-d₈	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-125835

CP-10 1 Publications Verification	PROTACs CDK	Cancer
CP-10 is a PROTAC connected by ligands for Cereblon and *CDK, with highly selective, specific, and remarkable CDK6* degradation (DC₅₀=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6 .

HY-164129

CDK4-IN-3	CDK Apoptosis	Cancer
CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC₅₀=25 nM, >10-fold selective over *CDK6). CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK*4-IN-3 is promising for research of solid tumors such as breast and lung cancers .

HY-112272A

Lerociclib dihydrochloride 2 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of *CDK4/CDK6*, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-50940A

AT7519 TFA 10+ Cited Publications AT7519M TFA	CDK	Cancer
AT7519 (AT7519M) TFA as a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-142696A

CDK6/PIM1-IN-1 hydrochloride	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 (Compound 51) hydrochloride is an orally active and potent dual *CDK6/PIM1* inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 hydrochloride inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 hydrochloride significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-169947

DDO-6079	CDK	Cancer
DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6 .

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both *cdk4* and *cdk6* and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

HY-142696

CDK6/PIM1-IN-1	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 is a potent and balanced dual *CDK6/PIM1* inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-168620

CDK6-IN-1	CDK	Cancer
CDK6-IN-1 (compound 4i) is a *CDK6* inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-201330

GDC-4198 RGT-419B	CDK	Cancer
GDC-4198 (RGT-419B) is an orally active *CDK4/2* inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .

HY-I0996

1,1-Dimethylethyl 4-(4-amino-3-pyridinyl)-1-piperazinecarboxylate	CDK	Cancer
1,1-Dimethylethyl 4-(4-amino-3-pyridinyl)-1-piperazinecarboxylate is the impurity of Palbociclib (HY-50767). Palbociclib is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK*4-mediated disorders, such as cancer .

HY-128669S

Abemaciclib metabolite M2-d6 LSN2839567-d₆	CDK	Cancer
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC₅₀s in the range of 1-3 nM. Anti-cancer activity .

HY-175013

CDK6/9-IN-2	CDK STAT Interleukin Related	Inflammation/Immunology
CDK6/9-IN-2 is a highly active dual inhibitor of *CDK6* (IC₅₀ = 15 nM) and *CDK9* (IC₅₀ = 22 nM). CDK6/9-IN-2 is selective for *CDK2, CDK8, and CDK11. CDK6/9-IN-2 inhibits the proliferation of HaCaT cells induced by IFN-γ/TNF-α* and suppresses the STAT3 pathway and the expression of inflammatory factors. CDK6/9-IN-2 can alleviate psoriatic dermatitis and is useful in psoriasis research .

HY-RS02393

Cdk6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk6 Mouse Pre-designed siRNA Set A Cdk6 Mouse Pre-designed siRNA Set A

HY-RS02394

Cdk6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk6 Rat Pre-designed siRNA Set A Cdk6 Rat Pre-designed siRNA Set A

HY-RS02392

CDK6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK6 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK6 Human Pre-designed siRNA Set A CDK6 Human Pre-designed siRNA Set A

HY-16297R

Abemaciclib methanesulfonate (Standard) LY2835219 methanesulfonate (Standard)	Reference Standards CDK	Cancer
Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

Cat. No.	Product Name	Target	Research Area

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both *cdk4* and *cdk6* and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0636

Eriocitrin 5 Publications Verification Eriodictyol 7-rutinoside; Eriodictyol 7-O-rutinoside	Flavonoids Classification of Application Fields Citrus limon (L.) Burm. F. Flavonones Rutaceae Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Apoptosis
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

HY-18981

Decursin 2 Publications Verification (+)-Decursin	Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC. Source Classification	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-116035

Nimbolide 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Disease Research Fields Source Classification Cancer	Wnt NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma ^[6] .

HY-N0636R

Eriocitrin (Standard) Eriodictyol 7-rutinoside (Standard); Eriodictyol 7-O-rutinoside (Standard)	Structural Classification Flavonoids Citrus limon (L.) Burm. F. Flavonones Rutaceae Phenols Polyphenols Plants Source Classification	Reference Standards Apoptosis
Eriocitrin (Standard) is the analytical standard of Eriocitrin. This product is intended for research and analytical applications. Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

HY-116035R

Nimbolide (Standard)	Triterpenes Structural Classification Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Source Classification	Wnt NF-κB CDK Apoptosis Reference Standards
Nimbolide (Standard) is the analytical standard of Nimbolide. This product is intended for research and analytical applications. Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 6 (CDK6)

Species:	Human (6)
Tag:	His (4) Tag Free (2) Avi (1) GST (3) Flag (2)
Source:	Sf9 insect cells (6)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701369

	CDK6-CCND3 Heterodimer Protein, Human (sf9) cdk6; CCND3; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D3	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND3 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND3 Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P701370

	CDK6-CCND3 Heterodimer Protein, Human (Active, sf9, GST, His) cdk6; CCND3; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D3	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND3 Heterodimer Protein, Human (sf9, GST, His) is a recombinant protein dimer complex containing human-derived CDK6-CCND3 Heterodimer protein, expressed by sf9 insect cells , with N-10*His, N-GST labeled tag.

HY-P702687

	CDK6-CCND1 Heterodimer Protein, Human (Active, sf9, GST, Flag, His) 1 Publications Verification cdk6; CCND2; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D2	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK6-CCND1 Heterodimer, expressed by Sf9 insect cells, with N-Flag, N-His, N-GST labeled tag.

HY-P701368

	CDK6-CCND2 Heterodimer Protein, Human (Active, sf9, GST, FLAG, His) cdk6; CCND2; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D2	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND2 Heterodimer Protein, Human (sf9, GST, FLAG, His) is a recombinant protein dimer complex containing human-derived CDK6-CCND2 Heterodimer protein, expressed by sf9 insect cells , with N-Flag, N-8*His, N-GST labeled tag.

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (sf9) cdk6; CCND1; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P702601

	CDK6 Protein, Human (sf9, His-Avi) 1 Publications Verification Cyclin-dependent kinase 6; Cell division protein kinase 6; cdkN6; EC:2.7.11.22	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6 Protein, Human (Sf9, His-Avi) is the recombinant human-derived CDK6, expressed by Sf9 insect cells, with N-His, N-Avi labeled tag. The total length of CDK6 Protein, Human (Sf9, His-Avi) is 326 a.a..

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-128669S

Abemaciclib metabolite M2-d6
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC₅₀s in the range of 1-3 nM. Anti-cancer activity .

HY-W654305

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

HY-18981S

Decursin-d6

Decursin-d₆ ((+)-Decursin-d₆) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

Host:	Rabbit (2)
Reactivity:	Human (2)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IP (1) WB (2) FC (1) ELISA (1)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80079

	CDK6 Antibody (YA511)	WB, IHC-P, ICC/IF, FC, IF-Tissue	Human
	CDK6 Antibody (YA511) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK6.

HY-P86594

	CDK6 Antibody (YA6286) Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	CDK6 Antibody (YA6286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK6.